Aralez Pharmaceuticals Inc. (ARLZ) Trading Down 0.4%
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)’s share price fell 0.4% during trading on Friday . The stock traded as low as $4.95 and last traded at $5.00, with a volume of 511,983 shares trading hands. The stock had previously closed at $5.02.
Several research firms recently commented on ARLZ. Guggenheim restated a “buy” rating and issued a $12.00 price target on shares of Aralez Pharmaceuticals in a research note on Monday, August 15th. Chardan Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Aralez Pharmaceuticals in a research report on Sunday, August 14th.
The company has a 50 day moving average of $4.33 and a 200 day moving average of $4.19. The company’s market capitalization is $326.20 million.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.08. The firm earned $12.60 million during the quarter, compared to the consensus estimate of $9.70 million. The firm’s revenue for the quarter was up 142.3% on a year-over-year basis. On average, analysts expect that Aralez Pharmaceuticals Inc. will post ($0.98) earnings per share for the current year.
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.